PHAR (Pharming Group) Company Cash Funds

Pharming Group N.V. automates protein production via robotic lines, minimizing manual labor. Market capitalization relies on the sale of patented treatments for rare pathologies, while R&D pipeline development is proceeding according to schedule. Current cash reserves demonstrate the business's financial stability, with the latest value recorded as 0.19, serving as the baseline criterion for the company's liquidity stress testing.
PHAR (Pharming): analytical breakdowns and indicator data

This metric reflects the volume of immediate liquidity, determining the issuer's ability to promptly settle short-term obligations without selling core assets. By analyzing the history of cash reserves, an investor assesses the financial cushion of Pharming Group N.V. (PHAR) for funding costly clinical trials and hiring scientists whose expertise remains indispensable even with the full automation of biopharmaceutical production in robotic reactors.